CD8A and ovarian cancer: Taken together, these data show that sitagliptin (i) increased CD8+ T cell/Treg ratios and (ii) reduced the expression of immunosuppressive cytokines, thereby altering the entire circulating immune landscape during the early dissemination stages of ovarian cancer.